Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
SYRE Stock | 23.34 0.25 1.06% |
About 62% of Spyre Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Spyre Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Spyre Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Spyre Therapeutics stock news signals to limit their universe of possible portfolio assets.
Spyre |
Spyre Therapeutics, Inc. , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease , today announced that it has initiated dosing of healthy volunteers in Phase 1 clinical trials of two investigational half-life extended anti-TL1A monoclonal antibodies.
Read at finance.yahoo.com
Spyre Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Spyre Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Spyre Therapeutics Fundamental Analysis
We analyze Spyre Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spyre Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spyre Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Spyre Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Spyre Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Spyre Therapeutics stock to make a market-neutral strategy. Peer analysis of Spyre Therapeutics could also be used in its relative valuation, which is a method of valuing Spyre Therapeutics by comparing valuation metrics with similar companies.
Peers
Spyre Therapeutics Related Equities
FATE | Fate Therapeutics | 1.19 |
| ||
KPTI | Karyopharm Therapeutics | 3.23 |
| ||
CRBU | Caribou Biosciences | 5.59 |
| ||
HOOK | Hookipa Pharma | 6.40 |
|
Complementary Tools for Spyre Stock analysis
When running Spyre Therapeutics' price analysis, check to measure Spyre Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spyre Therapeutics is operating at the current time. Most of Spyre Therapeutics' value examination focuses on studying past and present price action to predict the probability of Spyre Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spyre Therapeutics' price. Additionally, you may evaluate how the addition of Spyre Therapeutics to your portfolios can decrease your overall portfolio volatility.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |